In a meeting <a href="http://twinforms.com/products/index.php/transmission2017medhkuhk-ae77.pdf">carrdrug.rxlocal.com</a> Dr. Janet Woodcock, director of the FDA's drugs division,said during the discussion that the breakthrough pathway wasdesigned to accommodate new science, particularly targetedtherapies that may work in people with certain geneticmutations. She noted that just because the review process isspeeded up there is no guarantee of approval.